NCT02499601

CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)

CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) Safety and Feasibility

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: CorAssist Cadiovascular Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study objective is to demonstrate safety and feasibility of the CORolla® TAA during 12 months of follow up, and to evaluate the performance of the therapy in relieving symptoms and restore diastolic function in patients with heart failure and preserved ejection fraction.

Conditions

• Diastolic Heart Failure
• Diastolic Dysfunction

Interventions

Type	Name	Description
DEVICE	CORolla™ TAA device

Timeline

• Start date: 2015-09-01
• Primary completion: 2021-09-01
• Completion: 2024-09-01
• First posted: 2015-07-16
• Last updated: 2020-10-08

Locations

1 site across 1 country: Israel